Brief: Pasithea Therapeutics Signs CMC Development And Manufacturing Agreement For The Production Of PAS-004
18/01/2023 17:59
Jan 18 (Reuters) - Pasithea Therapeutics Corp KTTA.O :
* PASITHEA THERAPEUTICS SIGNS CMC DEVELOPMENT AND
MANUFACTURING
AGREEMENT FOR THE PRODUCTION OF PAS-004
* PASITHEA THERAPEUTICS CORP- ONTRACT WITH WUXI STA TO
MANUFACTURE
ACTIVE PHARMACEUTICAL INGREDIENT FOR PASITHEA'S MACROCYCLIC
* PASITHEA THERAPEUTICS CORP- PLANS TO INITIATE A PHASE 1
CLINICAL
TRIAL IN U.S. FOR NEUROFIBROMATOSIS TYPE 1 (NF1) IN 2H 2023
Source text for Eikon: ID:nGNXhxSHS
Further company coverage: KTTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pasithea Therapeutics
See all newsPasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 16 cents a share - Earnings Preview
Brief: Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data
Brief: Pasithea Therapeutics Announces Closing Of $60 Million Public Offering Of Common Stock
Pasithea Therapeutics jumps after $60 million public offering announcement